NCT02947815View on ClinicalTrials.gov

Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Blepharospasm
Interventions
DRUG

Clostridium Botulinum Toxin Type A

DRUG

Clostridium Botulinum Toxin Type A

Trial Locations (1)

Unknown

the catholic university of korea, Seoul ST. Mary's Hospital., Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY